期刊文献+

围绝经期子宫肌瘤的研究进展 被引量:13

Research progress of perimenopausal uterine myoma
下载PDF
导出
摘要 子宫肌瘤的发病年龄以40~50岁最多见,围绝经期是子宫肌瘤发生和病情发展的活跃期。目前,围绝经期子宫肌瘤已逐渐引起人们的重视,该文就其发生情况、病因、治疗方法及各种治疗方法的比较进行综述,同时就围绝经期子宫肌瘤进行性激素补充治疗也一并进行阐述。 Uterine myoma is more likely to develop in women aged 40-50 years, and perimenopause is the active phase of its occurrence and development. At present perimenopausal uterine myoma has obtained attention gradually. The article reviewed the incidence, etiology, treatment and comparison of various treatment methods, as well as hormone replacement therapy (HRT) for uterine myoma.
出处 《中国妇幼健康研究》 2013年第2期271-275,共5页 Chinese Journal of Woman and Child Health Research
关键词 围绝经期 子宫肌瘤 病因 治疗 性激素补充疗法 perimenopause uterine myoma etiology treatment hormone replace therapy (HRT)
  • 相关文献

参考文献26

  • 1Strissel P L, Swiatek J, Oppelt P, et al. Transcriptional analysis of steroid hormone receptors in smooth muscle uterine leiomyoma tumors of postmenopausal patients[ J]. J Steroid Biochem Mol Biol, 2007,107(1-2) :42-47.
  • 2Islam MS, Protic O, Giannubilo SR, et al. Uterine leiomyoma: available medical treatments and new possible therapeutic options [ J]. J Clin Endocrinol Metab,2013,98 (3) :921-934.
  • 3Lewicka A, Osuch B, Cendrowski K, et al. Expression of vascular endothelial growth factor mRNA in human leiomyomas[ J ]. Gynecol Endocrino1,2010,26 (6) :451-455.
  • 4Suzuki A, Kariya M, Matsumura N, et al. Expression of p53 and p21 ( WAF-1 ), apoptosis, and proliferation of smooth muscle cells in normal myometrium during the menstrual cycle : implication of DNA damage and repair for leiomyoma development [J]. Med Mol Morphol, 2012,45 (4) :214-221.
  • 5Huang L C, Ye J C, Hsieh C H, et al. PTEN, tau-AP-3, thymidylate synthase immunohistochemistry scoring expression in patients with uterine leiomyomas, uterine smooth muscle tumors of uncertain malignancy potential and uterine leiomyosarcomas[J]. Eur J Gynaecol Oncol ,2011,32 (5) :496-499.
  • 6Ohara N. Regulatory mechanism of Bcl-2 in uterine leiomyomas[J].Clin Exp Obstet Gynecol,2008,35 (4) :240-241.
  • 7Kayisli U A, Berkkanoglu M, Kizilay G, et al. Expression of proliferative and preapoptotic molecules in human myometrium and leiomyoma throughout the menstrual cycle [J]. Reprod Sci,2007,14 (7) :678-686.
  • 8Cramer S F, Marchetti C, Freedman J, et al. Relationship of myoma cell size and menopausal status in small uterine leiomyomas[J]. Arch Pathol Lab Med,2000,124 (10) : 1448-1453.
  • 9Ichigo S, Takagi H, Matsunami K, et al. Beneficial effects of dienogest on uterine myoma volume : a retrospective controlled study comparing with gonadotropin-releasing hormone agonist[J]. Arch Gynecol Obstet, 2011,284 ( 3 ) : 667-670.
  • 10Wang P H, Lee W L, Cheng M H,et al. Use of a gonadotropin- releasing hormone agonist to manage perimenopausal women with symptomatic uterine myomas [ J]. Taiwan J Obstet Gyneco1,2009 ,48 (2) :133-137.

同被引文献155

引证文献13

二级引证文献96

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部